Hansoh Pharmaceutical Group Company Limited
http://www.hansoh.cn/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hansoh Pharmaceutical Group Company Limited
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Chinese-Language Podcast: AZ收购亘喜，MNC本土重磅交易，2024展望
One week into 2024 and there have already been multiple deals between Chinese innovative drug developers and multinational partners, along with the significant acquisition of GracellBio by AstraZeneca. In this Chinese-language podcast, Brian Yang and Dexter Yan invite a guest speaker to discuss the reasons behind the particularly active China biotech deal-making scene.
J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout
CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice